Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS)
CNY 13.44
(-0.07%)
CNY 13.44
(-0.07%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 3.93 Billion | 3.71 Billion | 3.68 Billion | 2.91 Billion | 2.46 Billion | 1.7 Billion |
| Cost of Revenue | 3.27 Billion | 1.76 Billion | 1.59 Billion | 1.19 Billion | 1.2 Billion | 859.23 Million |
| Gross Profit | 659.13 Million | 1.94 Billion | 2.09 Billion | 1.71 Billion | 1.26 Billion | 841.09 Million |
| Operating Expenses | 2.19 Billion | 912.05 Million | 848.99 Million | 742.39 Million | 589.61 Million | 390.29 Million |
| Selling, General and Administrative Expenses | 464.96 Million | 514.83 Million | 524.82 Million | 483.15 Million | 375.5 Million | 259.71 Million |
| Research and Development Expenses | 372.29 Million | 263.66 Million | 220.95 Million | 187.53 Million | 166.34 Million | 101.18 Million |
| Other Expenses | 18.12 Million | 133.55 Million | 103.22 Million | 71.71 Million | 47.76 Million | 7.28 Million |
| Cost and Expenses | 4.22 Billion | 2.68 Billion | 2.44 Billion | 1.93 Billion | 1.79 Billion | 1.24 Billion |
| Operating Income | -331.9 Million | 1.17 Billion | 1.18 Billion | 876.98 Million | 667.64 Million | 460.43 Million |
| Interest Expense | 81.04 Million | 57.84 Million | 92.21 Million | 57.56 Million | 22.09 Million | 9 Million |
| Income Tax Expense | -105.31 Million | 98.85 Million | 139.83 Million | 117.97 Million | 74.12 Million | 43.16 Million |
| Earnings before Tax | -294.75 Million | 1.18 Billion | 1.2 Billion | 914.63 Million | 680.36 Million | 467.71 Million |
| Net Income | -189.44 Million | 1.09 Billion | 1.05 Billion | 806.12 Million | 604.96 Million | 424.54 Million |
| Earnings Per Share Basic | -0.12 | 0.68 | 0.67 | 0.51 | 0.38 | 0.35 |
| Earnings Per Share Diluted | -0.12 | 0.68 | 0.67 | 0.51 | 0.38 | 0.35 |
| Weighted Average Shares Outstanding | 1.57 Billion | 1.61 Billion | 1.58 Billion | 1.57 Billion | 1.57 Billion | 1.21 Billion |
| Weighted Average Shares Outstanding (Diluted) | 1.57 Billion | 1.61 Billion | 1.58 Billion | 1.57 Billion | 1.57 Billion | 1.21 Billion |
| Gross Margin | 0.17 | 0.52 | 0.57 | 0.59 | 0.51 | 0.49 |
| EBIT Margin | -0.01 | 0.38 | 0.38 | 0.38 | 0.30 | 0.30 |
| Profit Margin | -0.05 | 0.29 | 0.29 | 0.28 | 0.24 | 0.25 |
| EBITDA | -57.84 Million | 1.36 Billion | 1.38 Billion | 1.05 Billion | 745.87 Million | 516.75 Million |
| Earnings Before Tax Margin | -0.08 | 0.32 | 0.32 | 0.30 | 0.27 | 0.27 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 945.35 Million | 1.13 Billion | 1 Billion | 766.59 Million | 3.87 Billion | 838.18 Million |
| Cost of Revenue | 528.77 Million | 679.58 Million | 617.68 Million | 462.71 Million | 2.1 Billion | 432.62 Million |
| Gross Profit | 416.57 Million | 453.38 Million | 382.65 Million | 303.88 Million | 1.77 Billion | 405.55 Million |
| Operating Expenses | 125.04 Million | 212.36 Million | 182.73 Million | 1.52 Billion | 2.1 Billion | 155.34 Million |
| Selling, General and Administrative Expenses | 141.76 Million | 126.02 Million | 107.83 Million | 141.8 Million | - | 125.96 Million |
| Research and Development Expenses | 41.88 Million | 86.34 Million | 74.9 Million | 144.45 Million | - | 61.99 Million |
| Other Expenses | -58.61 Million | -1.82 Million | 1.73 Million | -1.24 Billion | -1.24 Billion | 4.7 Million |
| Cost and Expenses | 653.81 Million | 891.95 Million | 800.41 Million | 1.99 Billion | 4.2 Billion | 587.97 Million |
| Operating Income | 249.48 Million | 241.01 Million | 199.91 Million | -1.22 Billion | -331.9 Million | 215.94 Million |
| Interest Expense | 17.18 Million | 22.48 Million | 20.16 Million | 16.61 Million | 81.04 Million | 24.29 Million |
| Income Tax Expense | 46.51 Million | 31.34 Million | 23.3 Million | -223.03 Million | -105.31 Million | 3.88 Million |
| Earnings before Tax | 247.27 Million | 259.17 Million | 200.49 Million | -1.24 Billion | -294.75 Million | 218.7 Million |
| Net Income | 200.76 Million | 227.82 Million | 177.19 Million | -1.02 Billion | -189.44 Million | 214.8 Million |
| Earnings Per Share Basic | 0.12 | 0.14 | 0.11 | -0.64 | - | 0.13 |
| Earnings Per Share Diluted | 0.12 | 0.14 | 0.11 | -0.64 | - | 0.13 |
| Weighted Average Shares Outstanding | 1.61 Billion | 1.61 Billion | 1.61 Billion | 1.61 Billion | 1.61 Billion | 1.61 Billion |
| Weighted Average Shares Outstanding (Diluted) | 1.61 Billion | 1.61 Billion | 1.61 Billion | 1.61 Billion | 1.61 Billion | 1.61 Billion |
| Gross Margin | 0.44 | 0.40 | 0.38 | 0.40 | 0.46 | 0.48 |
| EBIT Margin | 0.28 | 0.25 | 0.23 | -1.54 | - | 0.28 |
| Profit Margin | 0.21 | 0.20 | 0.18 | -1.34 | -0.05 | 0.26 |
| EBITDA | 264.46 Million | 278.74 Million | 228.1 Million | -1.18 Billion | - | 237.73 Million |
| Earnings Before Tax Margin | 0.26 | 0.21 | 0.20 | -1.60 | -0.09 | 0.26 |
4GBL
HLZ
002277
AAB
NGIND
SURYODAY